Date: 2014-09-02
Type of information: Collaboration agreement
Compound: therapeutic targets, pathogenic immune cell types and biomarkers
Company: EMD Serono Research and Development Institute, Inc., a subsidiary of Merck KGaA, (Germany) Massachusetts General Hospital (USA - MA)
Therapeutic area: Autoimmune diseases
Type agreement:
Action mechanism:
Disease: systemic lupus erythematosus, lupus nephritis
Details: * On September 2, 2014, EMD Serono Research and Development Institute, a subsidiary of Merck KGaA, entered into a collaborative research agreement with Massachusetts General Hospital (MGH) to further the understanding of Systemic Lupus Erythematosus and Lupus Nephritis pathogenesis. In this collaboration, EMD Serono Immunology scientists will work jointly with MGH investigators to better characterize and validate the expression of investigative therapeutic targets, pathogenic immune cell types and biomarkers in SLE and LN patients. MGH investigators will prospectively collect biospecimens to be used in various translational research applications, including compound testing and gene expression analysis of target molecules. A major aim of this collaboration is to generate supportive data for the role of certain proteins targeted by clinical stage assets in the EMD Serono portfolio in LN pathogenesis, as well as enable early discovery efforts in Immunology.
This strategic alliance with MGH highlights the commitment of EMD Serono to develop medicines for SLE and LN and the commitment to engaging in strategic partnerships that leverage Massachusetts’ biotech innovation hub.
Financial terms:
Latest news:
